Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ:JUNS) priced a registered direct offering of 7,142,858 common shares, expected to raise approximately $2.0 million in gross proceeds. D. Boral Capital is exclusive placement agent, with closing targeted on or about May 21, 2026, under an effective Form S-3 shelf registration.
AI-generated analysis. Not financial advice.
Positive
- Registered direct offering to raise approximately $2.0 million in gross proceeds
- Issuance of 7,142,858 common shares under effective Form S-3 shelf
- Closing targeted on or about May 21, 2026, subject to customary conditions
Negative
- New issuance of 7,142,858 common shares implies equity dilution for existing holders
- Offering closing remains subject to satisfaction of customary closing conditions
News Market Reaction – JUNS
On the day this news was published, JUNS gained 10.25%, reflecting a significant positive market reaction. Argus tracked a peak move of +85.5% during that session. Argus tracked a trough of -49.3% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $11.61M at that time. Trading volume was exceptionally heavy at 2906.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
JUNS gained 10.25% with extreme volume while 3 momentum peers (e.g., SER, CAMP, QNTM) also moved up ~8–9%, indicating participation in a broader biotech/sector upswing alongside the company-specific offering.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 20 | Licensing term sheet | Positive | +10.3% | Non-binding ALA-002 U.S. rights term sheet with staged payments and royalties. |
| May 04 | Investor conference | Positive | +3.3% | Market Movers Investor Summit presentation to broaden investor outreach. |
| Apr 13 | Investor conference | Positive | -1.4% | Centri Capital Conference presentation on performance and growth plans. |
| Apr 07 | Advisory appointments | Positive | +2.6% | New Nugevia advisory board members adding distribution expertise. |
| Mar 31 | Investor conference | Positive | +15.8% | Emerging Growth Conference appearance focused on JOTROL progress. |
Recent news, mainly partnerships and investor events, has more often coincided with positive price reactions, though occasional divergences occur.
Over the last few months, Jupiter has combined capital-raising and business-development steps with active investor outreach. A $100M ALA-002 term sheet and multiple conference presentations previously coincided with price gains of up to 15.83%. Advisory board expansion for Nugevia tied into its CNS and nutraceutical strategy. Today’s registered direct offering, drawn from the $100,000,000 Form S‑3 shelf, fits an ongoing pattern of financing activity amid going‑concern and Nasdaq compliance pressures disclosed in recent SEC filings.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2026-04-15 permits up to $100,000,000 of securities via multiple offerings. The current $2.0M registered direct deal utilizes this shelf, with at least three recent 424B3 supplements indicating active use.
Market Pulse Summary
The stock surged +10.3% in the session following this news. A strong positive reaction aligns with recent momentum, as JUNS traded near its 52-week low yet moved 10.25% higher on volume 19.0x its 20-day average ahead of this $2.0M offering. The company has an effective $100,000,000 S-3 shelf and a history of frequent financings, so investors often reassessed dilution risk versus capital needs when interpreting similar capital-raising announcements.
Key Terms
registered direct offering financial
securities purchase agreement financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.
The gross proceeds of the offering are approximately
D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.
The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions.
The shares of common stock are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026.
A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC. Once filed, it will be available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com
Media Contact
Josh Birch, Media Relations Manager
KNB Communications
JBirch@KNBComm.com
